Implantica Management

Management criteria checks 3/4

Implantica's CEO is Peter Forsell, appointed in Jan 2015, has a tenure of 9.83 years. total yearly compensation is €204.27K, comprised of 99.8% salary and 0.2% bonuses, including company stock and options. directly owns 87.11% of the company’s shares, worth €786.27M. The average tenure of the management team and the board of directors is 4.3 years and 4.8 years respectively.

Key information

Peter Forsell

Chief executive officer

€204.3k

Total compensation

CEO salary percentage	99.8%
CEO tenure	9.8yrs
CEO ownership	87.1%
Management average tenure	4.3yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Peter Forsell's remuneration changed compared to Implantica's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-€25m
Jun 30 2024	n/a	n/a	-€24m
Mar 31 2024	n/a	n/a	-€23m
Dec 31 2023	€204k	€204k	-€24m
Sep 30 2023	n/a	n/a	-€20m
Jun 30 2023	n/a	n/a	-€20m
Mar 31 2023	n/a	n/a	-€21m
Dec 31 2022	€200k	€200k	-€21m

Compensation vs Market: Peter's total compensation ($USD215.59K) is below average for companies of similar size in the German market ($USD1.48M).

Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.

CEO

Peter Forsell (70 yo)

9.8yrs

Tenure

€204,274

Compensation

Dr. Peter Forsell founded Implantica AG in 2015 and serves as its Chief Executive Officer since 2015.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Peter Forsell	Founder & CEO	9.8yrs	€204.27k	87.11% € 772.5m
Andreas Öhrnberg	Chief Financial Officer	4.8yrs	no data	0.0084% € 74.8k
Stephan Siegenthaler	Chief Strategy Officer & Board Member	no data	no data	0.32% € 2.8m
Nicole Pehrsson	Chief Corporate Affairs Officer	2.4yrs	no data	0.17% € 1.5m
Amit Kukreja	Chief Market Access & Strategy Officer	3.8yrs	no data	no data
Jörg von Manger-Koenig	Company Secretary & Member of Advisory Board	no data	no data	no data

4.3yrs

Average Tenure

61yo

Average Age

Experienced Management: 8IM1's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Stephan Siegenthaler	Chief Strategy Officer & Board Member	4.8yrs	no data	0.32% € 2.8m
Jörg von Manger-Koenig	Company Secretary & Member of Advisory Board	no data	no data	no data
Liselott Kilaas	Independent Chair of the Board	4.8yrs	€36.02k	0.0099% € 88.1k
Tomas Puusepp	Independent Board Member	4.3yrs	€50.43k	0.0071% € 62.6k
Felix Zulauf	Member of Advisory Board	no data	no data	no data
Johan Bojs	Vice-Chairman of the Board	4.8yrs	€10.29k	0.047% € 414.6k
Piet Pattyn	Member of Scientific Advisory Board	no data	no data	no data
Steven Wilson	Member of Scientific Advisory Board	no data	no data	no data
Kaspar Z'graggen	Member of Scientific Advisory Board	no data	no data	no data

4.8yrs

Average Tenure

66yo

Average Age

Experienced Board: 8IM1's board of directors are considered experienced (4.8 years average tenure).

Implantica Management

Management criteria checks 3/4

Key information

Recent management updates

Implantica Announces Demise of Board Member Prof. Dr. Klaus Neftel

Chief Corporate Affairs Officer recently bought €108k worth of stock

Insufficient new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Implantica AG, Annual General Meeting, May 10, 2022

Recent updates

Third quarter 2024 earnings released: €0.09 loss per share (vs €0.019 loss in 3Q 2023)

Implantica AG to Report Q4, 2024 Results on Feb 14, 2025

Implantica AG (publ.) Submits FDA PMA Application Clinical Module 2 for RefluxStop for U.S. Market Approval

Implantica AG to Report Q3, 2024 Results on Nov 15, 2024

Implantica Ag (Publ.) Announces Highly Successful 2024 American Foregut Society Meeting Where Refluxstop Received Remarkable Pre- Launch Market Feedback

Implantica AG announces finalization of remarkable 5-year pivotal CE mark study results and gears up for the Module 2 submission of PMA application to FDA for RefluxStop

Implantica AG Announces Excellent Data from an Independent Study of 158 RefluxStop Patients from Two Centers in Germany - Presented at the AUGIS Meeting in UK

Implantica Announces Demise of Board Member Prof. Dr. Klaus Neftel

Second quarter 2024 earnings released: €0.09 loss per share (vs €0.018 loss in 2Q 2023)

Implantica AG Announces Refluxstop Pivotal 4-Year Study Results Published in the Prestigious Journal Surgical Endoscopy

Implantica Announces Continuing Progress in Modular PMA Application to FDA for Refluxstop

Implantica Announces New Health-economics Data Publication Showing RefluxStop's Superior Cost-Effectiveness for the Swiss Healthcare System

First quarter 2024 earnings released: €0.05 loss per share (vs €0.016 loss in 1Q 2023)

Implantica Submits U.S. FDA Premarket Approval (PMA) Application for RefluxStop® (first module)

Implantica Completes Human Factors Validation Study for RefluxStop as Part of the US FDA Premarket Approval Process

Full year 2023 earnings released: €0.34 loss per share (vs €0.074 loss in FY 2022)

Implantica AG to Report Fiscal Year 2023 Results on Apr 26, 2024

Implantica Ag Announces the First RefluxStop Procedures Completed At MIC Hospital in Berlin

Chief Corporate Affairs Officer recently bought €108k worth of stock

Third quarter 2023 earnings released: €0.019 loss per share (vs €0.02 loss in 3Q 2022)

Implantica AG (publ.)'s RefluxStop Offers for the First Time in the NHS in UK

Insufficient new directors

Implantica AG to Report Q4, 2023 Results on Feb 20, 2024

Implantica AG to Report Q2, 2023 Results on Aug 24, 2023

Implantica AG Announces RefluxStop Results Were Presented At the DDW Conference in Chicago

Implantica AG to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings released: €0.074 loss per share (vs €0.055 loss in FY 2021)

Full year 2022 earnings released: €0.30 loss per share (vs €0.055 loss in FY 2021)

Third quarter 2022 earnings released: €0.08 loss per share (vs €0.015 loss in 3Q 2021)

Third quarter 2022 earnings released: €0.08 loss per share (vs €0.015 loss in 3Q 2021)

High number of new and inexperienced directors

Second quarter 2022 earnings released: €0.08 loss per share (vs €0.042 loss in 2Q 2021)

First quarter 2022 earnings released: €0.07 loss per share (vs €0.03 loss in 1Q 2021)

Implantica AG to Report Q4, 2022 Results on Feb 17, 2023

Implantica AG to Report Q1, 2022 Results on May 11, 2022

High number of new and inexperienced directors

Implantica AG, Annual General Meeting, May 10, 2022

Full year 2021 earnings released: €0.055 loss per share (vs €0.039 loss in FY 2020)

Implantica Ag Announces Launch of Refluxstop™ in Uk

Implantica AG Announces Filing of Comprehensive eHealth Patent Applications for Its Platform Technology

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Implantica AG to Report Q4, 2021 Results on Feb 18, 2022

Implantica AG Appoints Paul Meadas as Chief Operating Officer

High number of new and inexperienced directors

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Vice-Chairman of the Board recently sold €1.4m worth of stock

Second quarter 2021 earnings released: €0.04 loss per share (vs €0.10 loss in 2Q 2020)

Implantica Achieves Regulatory Authorisation for RefluxStop™ in New Zealand

Implantica AG (publ) Makes Headway in Italy and Spain with Its Medical Device RefluxStop™

Implantica Advances in Sweden with its Medical Device Refluxstop™

Revenue misses expectations

Implantica AG to Report Q4, 2020 Results on Feb 25, 2021

Implantica AG (publ)'s RefluxStop™ Makes Strides in the UK

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age